Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

NCT01792700 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

648

Enrollment

OTHER

Sponsor class

Conditions

Helicobacter Infections

Interventions

DRUG: esomeprazole
DRUG: tripotassium dicitrate bismuthate
DRUG: metronidazole
DRUG: tetracycline
DRUG: moxifloxacin
DRUG: amoxicillin

Sponsor

Seoul National University Bundang Hospital